Meet the Experts Transporter Conference Seoul 2019

Meet the Experts Transporter Conference Seoul 2019


Welcome


As a pioneer in the drug transporter field for 20 years, SOLVO is dedicated to exploring the science of transporters and their role in xenobiotic efficacy and safety. With frequent Webinars hosted by respected scholars and professionals, as well as numerous peer-reviewed publications, our commitment and scientific contribution to the transporter field is well recognized.

After the great success of our events in SOLVO’s Meet the Experts: Transporter Conference series, we are pleased to announce that the tenth event will be held in Seoul on 14 November, 2019. With the Meet the Experts: Transporter Conference series, we took our commitment to the transporter field to a new level. The sessions will focusing on the most relevant and up-to-date aspects of transporter science and industry applications.

Venue: The conference will be organized at JW Marriott Hotel Seoul. One of the city's most distinguished destinations, JW Marriott Hotel Seoul welcomes travelers to the Gangnam District in five-star style. Address: 176, Sinbanpo-ro, Seocho-gu, Seoul 06546 South Korea

Our Sponsor:

 


Registration


Join leading transporter scientists to learn and discuss cutting edge research and developments


Early Bird Registration Fee until 31 August 2019: $50

Standard Registration Fee from 31 August 2019: $75


Payment can be made by wire-transfer or credit card. Please click here for credit card authorization form.

Cancellation policy: “Refunds will be issued for all requests received by the 20 August 2019. Refunds will not be issued for requests received after 20 August 2019.” Send cancellation request to marketing@solvo.com.

Your registration fee covers besides the conference program, lunchbox, coffee breaks, reception.

Registration Form for Seoul 2019

Please provide your Billing address:


Agenda


Chair: Joe Zolnerciks and Roelof de Wilde, SOLVO Biotechnology
Timing Duration Title Speaker
09:15- 30 Registration and Coffee with snacks
09:45- 15 Opening Péter Krajcsi, PhD, SOLVO Biotechnology
Durg Discovery and Development
10:00- 40 Keynote: The Next Frontier in ADME Science: Predicting and Verifying Tissue Drug Exposure Jashvant Unadkat, PhD, University of Washington
10:40- 30 Contribution of Xenobiotic Transporters to Drug Disposition Jasminder Sahi, PhD,Sanofi-Aventis (China)
11:10- 30 In Vitro Platforms for De-risking Nephrotoxicity Colin Brown, PhD, Newcastle University
11:40- 60 Lunch Seminar: Solutions by SOLVO to support your ADME-Tox research: Beáta Kovács, M, PhD, SOLVO Biotechnology
Barriers and Transporters
12:40- 40 Keynote: Regulation Mechanism of P-gp in the Blood-Brain Barrier Tetsuya Terasaki, PhD, Tohoku University
13:20- 30 Long-lasting Inhibition of OATPs: Update on the Mechanisms and Impact Wooin Lee, PhD, Seoul National University
13:50- 30 OATP2A1/SLCO2A1 Determines Prostaglandins’ Action by Distributing Them to the Required Place at the Right Time Takeo Nakanishi, PhD, Takasaki University
14:20- 30 Coffee Break
Transport and Metabolism
14:50- 40 Keynote: Food Effect on Intestinal Transporters ASBT and OATP2B1 Ikumi Tamai, PhD, Kanazawa University
15:30- 30 Integrated In Vitro and In Vivo Approaches to Drug Metabolism Investigations - a Study Case Massimiliano Fonsi, PhD, Citoxlab, a Charles River Company
16:00- 30 Nasal Route for CNS Drug Repurposing and Novel Delivery to the Brain Joan Z Zuo, PhD, Chinese University of Hong Kong
16:30- 20 Closing Remarks Péter Krajcsi, SOLVO
16:50- 70 Reception

*We reserve the right to change the Agenda.


Speakers


BROWN Colin, PhD

BROWN Colin, PhD

Associate Professor Institute for Cell & Molecular Biosciences, Medical School, Newcastle University Newcastle, UK

Biography

Dr Colin Brown was awarded a B.Sc and Ph.D in Physiology and Pharmacology from the University of St Andrews Scotland. He then was a Royal Society European Postdoctoral Research Fellow at the University of Zurich, Switzerland, followed by a Wellcome Trust Senior Fellowship in Biomedical Sciences at the University of Manchester.  Until recently, Colin was an Associate Professor at the University of  Newcastle where he focussed on developing in vitro models to study drug transport, drug interactions and toxicity in  kidney, developing  the aProximate in vitro PTC model.  In 2018, Dr Brown joined  Newcells Biotech as Director of ADMET Technologies. 

FONSI Massimiliano, PhD

FONSI Massimiliano, PhD

DMPK Director, Citoxlab, a Charles River Company, France

Biography

Dr. Fonsi is currently responsible of the DMPK department at Citoxlab, a Charles River company, with a role that is both managerial and scientific. He has more than twenty years’ experiences in drug discovery and development and particularly in the field of drug metabolism and metabolism mediated toxicity and DDI. Before joining Citoxlab, he worked at Merck MSD, UCB, Addex, where he has actively participated in the discovery of Zolinza, Isentress, Niraparib, Grazoprevir and other candidate drugs currently in clinical phase. His area of competence covers both discovery and regulatory ADME, including toxicokinetics.  Dr. Fonsi is actively involved, in collaboration with academia and biotech companies, in developing new in vitro ADMET models (essentially for hepatotoxicity and thyroid toxicity via (secondary) hepatic enzyme modulation) for the determination of likelihood of human adverse outcomes using complementary in vitro and in silico models for interspecies extrapolation. Dr. Fonsi has been member of the scientific committee of the French “Groupe de Métabolisme et Pharmacocinétique” (GMP) congress in the recent past. Starting from 2019 he is also member of the steering board of the GMP organization.

LEE Wooin, PhD

LEE Wooin, PhD

Associate Professor, College of Pharmacy, Seoul National University, Seoul, Korea

Biography

Wooin Lee obtained her PhD degree at the Department of Pharmaceutical Sciences, College of Pharmacy, University at Buffalo, SUNY in the USA. She did her postdoctoral training at the Division of Clinical Pharmacology at Vanderbilt University. After that, she joined the research faculty working closely with clinical oncologists and the early drug development team at the Vanderbilt-Ingram Cancer Center. She was an Assistant and Associate Professor at the Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky. In 2014, she moved back to South Korea and is currently an Associate Professor at the College of Pharmacy, Seoul National University. Her research interest lies in understanding the genetic, epigenetic and molecular bases for variable drug response and drug interactions with a focus on membrane transporters and developing novel anticancer drugs targeting the proteasomes and their delivery strategies to achieve desirable pharmacokinetic and pharmacodynamic profiles. She has also been pursuing research in pharmacokinetic modeling and simulation using preclinical and clinical data. She has authored over 80 peer-reviewed publications. 

NAKANISHI Takeo, PhD

NAKANISHI Takeo, PhD

Professor, Takasaki University of Health and Welfare Faculty of Pharmacy, Japan

Biography

Dr. Takeo Nakanishi has more than 20 years of experience in biopharmaceutics. He received his Ph.D. in pharmaceutical sciences from Kanazawa University, and later had post-doc terms in Medical College of Georgia, Augusta, GA and Greenebaum Cancer Center, the University of Maryland at Baltimore, MD, USA. He currently appointed to a professor in Faculty of Pharmacy, Takasaki University of Health and Welfare. In his academic career, he has focused on 1) MDR transporters, in particular, ABCG2, in cancer cells, and 2) molecular biology of physiologically important transporters. For the past decade, he has been working in Kanazawa University to understand the pathophysiological significance of solute carriers for amino acids, urate, steroid hormones, and prostaglandins. Research on unappreciated roles of these carriers may hold much promise for new approaches in developing effective therapies for refractory diseases related to cancer and chronic inflammation.   

SAHI Jasminder, PhD

SAHI Jasminder, PhD

Senior Director, Department of Translational Medicine and Exploratory Development, Sanofi R&D, China

Biography

Jasminder Sahi obtained a Ph.D. degree (Pharmacognosy, 1991) from Panjab University, India and then participated in a post-doctoral program in the Department of Physiology and Biophysics, University of Illinois at Chicago.  She started her career in the Pharmaceutical Industry in the Department of Pharmacokinetics and Drug Metabolism (Parke Davis R&D), which was subsequently acquired by Pfizer Global Research and Development.  In 2006, she joined a new venture (CellzDirect) as the Vice President R&D.  In 2012 she moved to Shanghai China, as Head of DMPK for GlaxoSmithKline Research and Development and in 2015 made the transition to Sanofi R&D leading the DMPK efforts in the Asia Pacific region.   Jasminder’s research focus is on transporters and induction of drug metabolizing enzymes, using primary hepatocytes. While her initial forays into transporter research involved ion transport to understand CFTR, at Pfizer she changed her focus to xenobiotic transporters, with the goal of improving drug disposition, delivery and safety.   She has worked extensively with hepatic and renal transporters as well as the blood-brain-barrier.  She is an elected member of the ISSX council, a reviewer for six journals and has authored over 40 peer-reviewed publications. 

TAMAI Ikumi, PhD

TAMAI Ikumi, PhD

Professor Institute of Medical, Pharmaceutical and Health Sciences, Faculty of Pharmaceutical Sciences, Kanazawa University Kanazawa, Japan

Biography

Education and Professional Experiences;

BS, Kanazawa University 1982, Ph.D; University of Tokyo 1988; Post-doctoral Fellow, University of Chicago and University of Michigan (1989-1991); Professor, Tokyo University of Science (2002-2008); Kanazawa University, Institute of Medical, Pharmaceutical and Health Sciences 2008-present. Head, Venture Business Laboratory, Kanazawa University (2014 – present).

Professional Affiliations:

Japanese Society for the Study of Xenobiotics (JSSX); Academy of Pharmaceutical Science and Technology, Japan (APSTJ); Pharmaceutical Society of Japan (PSJ); Japanese Society of Gout and Nucleic Acid Metabolism; American Association of Pharmaceutical Scientists (AAPS); American Society for Pharmacology and Experimental Therapeutics (ASPET); International Society for the Study of Xenobiotics (ISSX).

Board of Committee:

Committee Member of Food Safety Commission, Cabinet Office, Government of Japan (2006 - present); Associate Editor, Biopharmaceutics and Drug Disposition (2009 - present); Editor, Pharmaceutical Research (2017 - present); Councilor, JSSX (2006 – 2013, 2017 - present); Councilor, ISSX (2010 - 2013); Editor in Chief, Drug Metabolism and Pharmacokinetics (DMPK) (2010 - 2013); Associate Editor, Biological Pharmaceutical Bulletin. (2006 - 2008); Editorial Board Member for Journal of Pharmaceutical Sciences, Molecular Pharmaceutics, Pharmaceutical Research and Drug Metabolism and Disposition.

Research of Interest:

Transporters related to Drug-Drug Interaction, Drug-Food Interaction, Drug-induced Toxicity, Regulation of Uric Acid and Prostaglandins, Drug Absorption and Pharmacokinetics.

TERASAKI Tetsuya, PhD

TERASAKI Tetsuya, PhD

Distinguished Professor Membrane Transport and Drug Targeting Laboratory, Graduate School of Pharmaceutical Sciences, Tohoku University Sendai, Japan

Biography

Dr. Tetsuya Terasaki graduated Kanazawa University in 1977 and received Ph.D. degree from University of Tokyo in 1982. He was appointed Full Professor of Tohoku University in 1996 and the University Distinguished Professor of Tohoku University in 2008. He received the Ebert Prize from American Pharmaceutical Association in 1985, the Meritorious Manuscript Award from American Association of Pharmaceutical Scientists in 1996 and 2010, together with three Research Achievement Awards. In April 2013, he received the Medal of Honor with Purple Ribbon, bestowed by the Government of Japan to the most highly honored scientists. His major research interests are the molecular pharmacology of blood-brain barrier function and the pharmacoproteomics. He published extensively in journals, with 309 original research articles and 70 review articles and contributed chapters to over 50 books.

UNADKAT Jashvant, PhD

UNADKAT Jashvant, PhD

Professor of Pharmaceutics in the School of Pharmacy, University of Washington, Seattle, US

Biography

Jashvant (Jash) Unadkat, Ph.D. is the Milo Gibaldi Endowed Professor at the School of Pharmacy, University of Washington, Seattle.   He received his Bachelor degree in Pharmacy (B.Pharm.) from the University of London (1977), his Ph.D. from the University of Manchester (1982) and his postdoctoral training at the University of California at San Francisco (1982-85).  Dr. Unadkat studies the mechanisms of transport and metabolism of drugs, including during pregnancy.  Dr. Unadkat has published more than 200 peer-reviewed research papers.  He is a fellow of AAAS, AAPS, JSSX, and the founding co-chair (1999-2001) of the focus group of AAPS on Drug Transport and Uptake.  Dr. Unadkat received the AAPS Research Achievement Award in 2012.  Dr.  Unadkat created and leads the UW Research Affiliates Program on Transporters (UWRAPT), funded by pharmaceutical companies and UWPKDAP, a NIDA funded Program Project grant (P01) on drug disposition during pregnancy.